The Mclean Hospital Corporation

University of Delhi

Kim, Kwang-soo

Kwang-Soo Kim

Chun-Hyung Kim

Deepak Kumar

Sunny Manohar

Diwan S Rawat

Shamseer Kulangara Kandi

Satyapavan Vardhineni

Anuj Thakur

Young Cha

Mohit Tripathi

Ummadisetty Chinna Rajesh

Panyala Linga Reddy

Ole Isacson

Sangmi Chung

Dong-Youn Hwang

Disclosed herein are methods of generating induced pluripotent stem cells. The method involves providing a quantity of somatic or non-embryonic cells, contacting the contacting the somatic or non-embryonic cells with a quantity of one or more programming factors and one or more RNA molecules, and culturing the somatic or non-embryonic cells for a period of time sufficient to generate at least one induced pluripotent stem cell. Various reprogramming factors and RNA molecules for use in the methods are disclosed herein. Also disclosed are cell lines and pharmaceutical compositions generated by use of the methods.

Synergistic genome-nonintegrating reprogramming by microRNAs and transcription factors

Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegenerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.

Aminoquinoline derivatives and uses thereof

Disclosed herein are methods of generating induced pluripotent stem cells. The method involves providing a quantity of somatic or non-embryonic cells, contacting the contacting the somatic or non-embryonic cells with a quantity of one or more reprogramming factors and one or more RNA molecules, and culturing the somatic or non-embryonic cells for a period of time sufficient to generate at least one induced pluripotent stem cell. Various reprogramming factors and RNA molecules for use in the methods are disclosed herein. Also disclosed are cell lines and pharmaceutical compositions generated by use of the methods.

Provided are methods of isolating a novel cell population of midbrain dopaminergic neuronal progenitor cells derived from stem cells using a novel combination markers. The cell population may be used for cell therapies for the treatment of Parkinson's disease and as substrates in pharmacological assays.

Methods for purifying midbrain dopaminergic neural progenitor cells

Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.

This invention features methods and compositions useful for the treatment and diagnosis of attentional disorders including attention deficit hyperactivity disorder (ADHD). Also disclosed are methods for identifying compounds useful for such therapy.

Diagnosis of attention deficit hyperactivity disorder

The invention features an enhancer cassette and methods of its use. The enhancer cassette has the formula [X&#x2212;Y], wherein each X is independently a cell type-specific enhancer element; Y is absent or is a mono or polynucleotide that has between one and thirty nucleotides; and n is an integer between five and fifty, inclusive.

Multimerized enhancer domains for cell-specific expression

The invention features an enhancer cassette having the formula [X-Y], wherein each X is independently a noradrenergic cell-specific enhancer derived from a DBH gene; Y is absent or is a mono or polynucleotide that has between one and thirty nucleotides; and n is an integer between three and twenty, inclusive.

Multimerized DBH enhancer domains

The invention features an enhancer cassette having the formula &lsqb;X-Y&rsqb; , wherein each X is independently a noradrenergic cell-specific enhancer derived from a DBH gene; Y is absent or is a mono or polynucleotide that has between one and thirty nucleotides; and n is an integer between three and twenty, inclusive.

Growing community of inventors

Lexington, MA, United States of America

Kwang-Soo Kim